
|Videos|March 30, 2021
Relapsed/Refractory HER2+ Metastatic Breast Cancer
Author(s)Targeted Oncology
Experts in breast cancer review clinical cases, discuss individualized treatment options and key clinical trials.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5










































